Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Director · Chairman, Pres. & CEO | September 28, 2026 | September 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date September 28, 2026 · Filed September 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par valueSEC Table I · non-derivative | Direct | 764,871 |
Reported balance
After 2026-09-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-28 · Grant · Acquired 400,000 · Balance 764,871 F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2: Includes shares of common stock underlying unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
F2: Includes shares of common stock underlying unvested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2026 Filed Sep 29, 2026 20:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-007483 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 764,871 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| September 22, 2026 Filed Sep 23, 2026 20:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 2,000 | $1.03 | $2,057.80 |
DisclosureSEC source: 0001683168-26-007321 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,871 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | Tax withholdingCommon Stock, $.0001 par value | 68,550 | $1.03 | $70,606.50 |
DisclosureSEC source: 0001683168-26-007159 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,871 F1 · kind: The transaction represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 20:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 10,000 | $1.06 | $10,600.00 |
DisclosureSEC source: 0001683168-26-006592 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,421 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 20:02 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001683168-26-005164 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,421 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 12:56 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-000803 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,421 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 21:05 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 5,000 | $1.03 | $5,150.00 |
DisclosureSEC source: 0001683168-26-000013 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,421 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 13:10 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 5,000 | $1.02 | $5,100.00 |
DisclosureSEC source: 0001683168-25-009349 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,421 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 17:54 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 5,000 | $1.14 | $5,700.00 |
DisclosureSEC source: 0001683168-25-008639 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,421 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 17:47 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 5,000 | $1.27 | $6,350.00 |
DisclosureSEC source: 0001683168-25-008537 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,421 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 12:28 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-006954 · ownership.xml · nonDerivative · entry 2 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,421 F2 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F3 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 12:28 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | Tax withholdingCommon Stock, $.0001 par value | 4,111 | $2.32 | $9,537.52 |
DisclosureSEC source: 0001683168-25-006954 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres. & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,421 F1 · kind: The transaction represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $0.0001 par value | 2,000 | $2.42 | $4,840.00 |
DisclosureSEC source: 0001062993-25-011424 · form4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,149 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:43 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $0.0001 par value | 1,500 | $2.75 | $4,125.00 |
DisclosureSEC source: 0001062993-25-011326 · form4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,149 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| May 22, 2025 Filed May 23, 2025 13:04 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $0.0001 par value | 1,200 | $1.78 | $2,135.88 |
DisclosureSEC source: 0001062993-25-010155 · form4.xml · nonDerivative · entry 2 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,649 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F2 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. Read SEC document |
| May 21, 2025 Filed May 23, 2025 13:04 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $0.0001 par value | 3,000 | $1.77 | $5,310.00 |
DisclosureSEC source: 0001062993-25-010155 · form4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,449 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F2 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 18:59 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $0.0001 par value | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-006373 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Chairman, Pres & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,832 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one year on the first anniversary. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 21:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 1,000 | $0.74 | $740.00 |
DisclosureSEC source: 0001683168-24-004126 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,990 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 21:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 1,000 | $0.75 | $750.00 |
DisclosureSEC source: 0001683168-24-004089 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,990 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:42 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,500 | $0.91 | $2,275.00 |
DisclosureSEC source: 0001683168-24-001216 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,990 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 00:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | Tax withholdingCommon stock, $0.0001 par value | 1,804 | $0.76 | $1,371.04 |
DisclosureSEC source: 0001683168-24-001134 · ownership.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,490 F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 23:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | Tax withholdingCommon stock, $0.0001 par value | 917 | $1.51 | $1,384.67 |
DisclosureSEC source: 0001209191-23-051706 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,294 F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 22:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 1,000 | $2.84 | $2,840.00 |
DisclosureSEC source: 0001209191-23-041254 · doc4.xml · nonDerivative · entry 2 Bitterman Robert J · CIK 0001304395 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,211 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 1,000 | $2.88 | $2,880.00 |
DisclosureSEC source: 0001209191-23-041254 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,211 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 00:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011909 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,211 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in two equal annual installments commencing on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 22:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,000 | $0.39 | $780.00 |
DisclosureSEC source: 0001209191-22-061471 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Interim Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,541 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 21:30 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,000 | $0.39 | $780.00 |
DisclosureSEC source: 0001209191-22-060358 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Interim Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,541 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 21:30 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,000 | $0.43 | $860.00 |
DisclosureSEC source: 0001209191-22-060009 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Interim Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,541 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| November 29, 2022 Filed Nov 29, 2022 21:30 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 215 | $0.40 | $86.00 |
DisclosureSEC source: 0001209191-22-058942 · doc4.xml · nonDerivative · entry 2 Bitterman Robert J · CIK 0001304395 · Director · Interim Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,541 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 21:30 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,500 | $0.42 | $1,050.00 |
DisclosureSEC source: 0001209191-22-058942 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Interim Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,326 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| November 16, 2022 Filed Nov 16, 2022 22:06 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseSeries D Preferred Stock, $0.0001 par value | 1 | $1,750.00 | $1,750.00 |
DisclosureSEC source: 0001209191-22-057333 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director · Interim Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 F1 · balance_after: The outstanding share of Series D Preferred Stock shall be redeemed in whole, but not in part, at any time: (i) if such redemption is approved by the Board of Directors in its sole discretion or (ii) automatically and effective upon the approval of an amendment to the Certificate of Incorporation to implement a reverse stock split. Upon redemption, the share of Series D Preferred Stock will receive consideration of $1,750.00 in cash. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 00:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051984 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,826 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 00:59 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010372 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,826 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 02:05 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017570 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,826 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Effective as of 12:01 a.m. Eastern Time on January 15, 2020, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-55. Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 00:38 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 300,000 | $0.10 | $30,000.00 |
DisclosureSEC source: 0001209191-19-057518 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,440 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 02:05 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010824 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,440 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| August 01, 2018 Filed Aug 4, 2018 01:31 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045457 · doc4.xml · nonDerivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,440 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:20 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-17-007732 · doc4.xml · derivative · entry 1 Bitterman Robert J · CIK 0001304395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-02-01 F1 · derivative.exercise_date: The stock option vests in equal quarterly installments over one year beginning on the first quarterly anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.